Azelastine is a nov el antiallergy medication currently under investigation for the treatm ent of allergic rhinitis and asthma. Pharmacologic studies in laboratory animals and in vitro model sys tems indicate that azelastin e exerts multiple actions including modulation of airways smooth mu scle response. interference with inflammatory pro cesses, and inhib ition of allergic reactions. In a previous controlled clini cal trial . azela stine nasal solution (ASTELIN N.S.TM) demonstrated effectiveness in controlling symptoms ofseasonal allergic rhiniti s (SAR) . The objective of this 2-week double-blind. parallel-group study was to furth er asse ss the effectiveness ofazelastine nasal solution in improving allergic rhinitis symptoms. Two hundred forty-seven patients (';?12 years) with symptomatic SAR who satisfied a minimum symptoms sco re durin g a I-week , single-blind, baseline evaluation period were randomized to receive azelastine 2 spra ys p er nostril bid, azelastine 2 sprays per nostril qd. chlorpheniramine 12 mg bid, or placebo using a doubledummy technique to insure blinding. The primary efficacy variables wcrc changes in Major Symptom Complex (nose blows , sneezes, runn y nos etsniffles, itch nose, and watery eyes) lind Total Symptom Complex (Major plus itchy eyesl ears/throat/palate, cough, andpostnasal drip [severlty scores.
Introduction
Azelastine hydrochloride, a novelinvestigational agent,is a phthalazinone derivative' with a unique pharmacologic profile that does not permit its classification into any of the pharmacologic groups currently indicated for the treatment of upperand/or lowerairwaydisorders (i.e., antihistamines, beta agonists, corticosteroids, theophylline, or disodium cromoglycate-like drugs). Studies in laboratory animals and ininvitromodelsystems indicated thatazelastine hydrochloride is a long-acting agent with multiple pharmacologic actions, including antiallergic properties and the ability to modulate airway smooth-musclc response and to interfere with inflammatory processes. " Among the antiallergic properties of azelastine are its ability to inhibit peritoneal mast-cell histamine release in rats,10·II to inhibit histamine release from human basophils," and to block allergeninduced bronchospasm in the rat!' and guinea pig." In addition, azelastine interferes with the synthesis and release oflcukotrienes fromhumanpolymorphonuclearleukocytes." Azelastine also interferes with inflammatory proccsses'"" by inhibiting the Ca't-dependent steps in the synthesis and secretion of inflammatory chemical mediators from mast STOR MS, PEARLMAN , CHERV INSKY, GROSSMAN , HALVERSON, FREITAG , WIDLITZ ce lls, leucocytes, and other ce ll types in anima ls and humans.":" Previous short-term studies of aze lastine nasal solution (ASTELIN N.S.TM ) dem onstrated that dosage reg ime ns of2 sprays per nostril qd and 2 sprays per nostril bid are safe and effective in the treatm ent of seasona l alle rgic rhinitis (SA R): 23.24 These findin gs are supported by 2-week and 4- week trials with aze lastine nasal solution." :" In this study , co nducted from May to August 1990 at five sites during the height ofthe allergy season for each location, the efficacy and safety of the two dosage regimens of aze lastine nasal so lution were compared with placebo in the long-term treatment of patients with symptomatic SAR.
Methods

Patients
All patient s were at least 12 yea rs of age and had a history and diagnosis o f SA R req uiring pharm acolo gic therapy for at least the previous 2 years. Patient s also dem onstrat ed allergy to at least one seasonal allergen as co ntinned by a prick/ scra tch skin test within the previou s yea r, or ifnot available, at the time of the screening visit. A signed informed consent docum ent was required prior to the screening per iod.
Patient s with a history of asthma were enrolled only if they had not taken chronic antiasthma medication for at least 24 co nsec utive months prior to study entry or if they had a history of exe rcise-induced broncho spasm and used a betaagonist inhaler only in co nj unction with exercise.
Pregnant and nursing wo me n were not eligible for study participation ; wome n of childbearing potential were includ ed provided they used appropriate methods of cont raception. Patient s with an upper respiratory tract infection, clinically significant nasal anatomical defects, or other significant medical conditions were excluded, as were those who had experienced an episode of acute sinusitis within 30 days of study entry and those receivin g a cha nging immunotherapy regimen or beginning immunotherapy.
Th e following med ication s were restricted prior to the baseline evaluation: ca lcium channel blockers, beta blockers, intran asal or optical crorn olyn, reserpin e, MAO inhib itors,or inhal ed stero ids within 14 days; H,-recept or antagonists or decon gestants within 48 hours; systemic steroids within 30 days; and astemizole within 60 days. In addition, patient s Adverse experiences lollowing the administration of lidocaine are si milarin nature 10 those observedwithother amide local anesthetic agents. Theseadverse experiences are,In general, dose-related and may resun from high plasma levels caused byexcessivedosage or rap idabsorption.or may result from ahypersensitivity. idiosyncrasy. or diminished tolerance onthepart of the patient. Ser iousadverse experiences are generally systemic in nature. The lollowrng types arethosemost commonly reported: There have beenrare reports of endotracheal tubeocclusion associatedwith the presence 01dried jellyresidue in the inner lumenof thetube. (Seealso WARNINGSandDOSAGE ANDADMINISTRATION.) Central Nervous System: CNS manif estations are excitatory and/or depressant and may be characterized by Iight headedness, nervousness. apprehension, euphoria. confusion. dizziness, drowsiness. tinnitus. blurr ed or doublevision,vomiting,sensations 01heat.cold or numbness, tWitching. tremors, convul sions, unconsciousness, respiratory depression, and arrest. The excitatory manifestations may be very brief or may not occur at all, in, which case thefirst manif estation of toxicit y may be drowsiness merging into unconsciousness and respiratory arrest.
Drowsiness following the admin'stratiun of lidocaine is usuall y an early sign of a highbloodlevel01thedrug and may occuras aconsequencecf rapid absorption. Cardiovascular SysterA: Cardiovascular manifestations are usually depressan t and are Characterized by bradycardi a, hypotension. andcardi ovascutar coll apse, which may leadto cardiac arrest. Allergic: All ergic reactions are characterized by cutaneous lesions, urticaria, edema, or anaphylactoid reactions. Al lergiCreactions mayoccurasa result 01senSitivityeitherto thelocal anesthetic agent or toother com ponenl s in theformulati on. All ergic reactions as a resuU 01 sensi tivity 10 lidocaine are ext remely rareand. II they occur. should bemanaged by convenuonatmeans. Thedetectionof sensitivity byskintesting is 01doubtfulvalue.
OVERDOSAGE
Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics.(SeeADVERSEREACTIONS. WARNING S.and PRECAUTIONS.) Management 0' Loc al Anesthetic Emergencies: The first consideration Is prevention. best accom£lished by care ful and constant monitoring of cardiovascular and respiratory vital signs and the patient s state 01 consciousness aller each locat anesthetic administration. At the first sign 01 change, oxygen should be administered. The first step in the management 01 convulsi onsconsists 01Immediate att ention to the maintenance of a pat ent airway and assistedor controlled ventilationwi th oxygenand a deliverysystem capable of permitting immediate positi veai rway pressureby mask. Immediately alter the institution of theseventilatory measures. theadequacy 01 Ihecirculation should be evaluated, keepingin mind that drugs usedto treat coovuisons sometimesdepress the circul ation when administer edIntravenously. Should convulsions persist despite adequate respiralory support, and if the status 01 the circulation permits, small increments of an ultra-short acting barbiturat e (such as thiopental or th/amylal)or a benzodiazepine (suchas di azepam) maybeadministered intravenously. The clinician should be familiar, prIor to use of local anesthetics, with these anticonvulsant drugs. Support ive treatment 01 circulatory depr ession may require admi nist ration 01intravenous fiui ds and. when appropriate, a vasopressor as directed bythecllnicai situat ion(e.g.•ephedrine). Many drugs used during Ihe conduct 01 anesthesla are considered potential Iriggeringagents for familial malignant hyperthe rmia. Since It Is not known whether amide-type local anesthetics may trigger thiS reaction and sincethe need for suppl emental general anesthesia cannot be predicted in advance, It Is suggesled that a standard protocol lor management shouid be availabl e. Early unexplai ned signs of tachycardi a, tachypnea, labi le biood pressure.and met abolic acidosis may precede temperature elevation.
Successful outcom e Is dependent on early diagnosis. prompt discontinuance 01 the suspect tnggermg agent(s) and institution of trea tment. Including oxygen therapy, lndlcated supportive measures and dantrolene(consult dantrolenesodium Intr avenous packageinsertbefore using) . Infermatlen ler Patients: When topical anestheticsare used in the mouth. thepatient shouldbe aware that the production01topical anesthesia may Impai r swallowing and thusenhance thedanger 01aspi ration. for this reason, lood should notbeIngested lor 60minutes lollowinguse01local anesmenc preparations in the mouth or throalarea.This is particularlyimportant In children because 01their Irequency of eallng. Numbness of the tongue or buccal mucosa may enhance thedanger 01 unlntenl/onal biting trauma. f ood and chewing gumshould not belaken while themouth or throat areais anesthetized. Carcinogenesis, Mutagenesis, Impalrmenl 01 fertllllv : Studies ot lidocaine in animals to evaluate the carcinogenic and mutagenic porentialor theeffect on lertilityhave notbeen conducted. U18 In Pregnancy: Teratogenic Eftects. Pregnancy Calegory B.Reproductionstudieshave been perlormed Inratsat doses upto 6.6 times thehuman doseand have revealedno evi denceof harm to thefetus caused by lidocaine. There are. however. no adequate andwell -cont rolled studies in pregnant women. Animat reproducl/onstudiesare not always predi ctive 01hum anresponse. General consi deration shouldbe given to this fact befor e administering lidocaine to women 01 childbearing potential, especially dUring early pregnancy when maximum organogenesis takes place . Labor end Delivery: Lidocaine is not contraindicatedIn labor and deli very. Should Xylocaine2% Jell y be usedconcomitantly wilhother products contai ning lidocaine, the totaldosecontributed byall tcrmuiat lons must bekept in mind.
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Study Design
This was a multicenter, doubleblind, randomized, placebo-and positive-controlled, parallelgroup study in patients with symptomatic SAR. Following a 1week, single-blind, placebo evaluation period, patients who satisfied the minimum symptom criteria (a Major Symptom Complex [MSC] severity score of at least 10 [defined below] on any 4 days during baseline with at least Qne symptom Qfat least moderate intensity on each ofthe 4 days) were randomized offour treatments for 2 week s: azelastine nasal solution, 2 sprays per nostril qd (total daily dose = 0.55 mg) , azelastine nasal solution, 2 sprays pernostril bid (total daily dose = 1.1 mg), chlorpheniramine maleate (Chlor-Trimeton® Repetabs®) 12 mg bid, or matching placebo tablets and nasal solution bid. A doubledummy technique was used to maintain the double-blind conditions. Chlorpheniramine maleate was used as the active control to validate the study design.
Each patient received a diary with instructions to record rhiniti s symptoms twice daily using the symptom scoring system shown in Table I . After I week and 2 weeks of treatment with doubleblind medication, patients returned to the study site for physical and nasal examinations and a diary review. A follow-up evaluation was done I week after completion of or early withdrawal from double-blind therapy.
The primary efficacy variables were changes from baseline in the Total Symptom Complex (TSC) and/or Major Symptom Complex (MSC) severity scores. The TSC consists of those symptoms frequently seen in the rhinitis profile; the MCS consists of symptoms most predominant in the symptom profile. The scores for five individual symptoms (sneezes, runny nose/sniffles, nose blows, itchy nose, and watery eyes) who had experienced a clinically significant adverse drug experience during a previous investigational drug study with azelastine were excluded from study participation . The changes were summarized with means and standard errors and tested by a paired t-test. In addition, the comparability of the treatment groups at baseline and after each week of double -blind treatment were assessed using a two-way analysis of variance (AN aYA). The total duration of exposure to study medications and the number of patients exposed were summarized by frequency distribution.
The level ofsignificance for all tests was set at P:S;.05. All pairwise treatment comparisons utilized two-sided tests.
Results
Two hund red forty-seven patients, ages 12 to 69 years, satisfied the inclusion and exclusion criteria and were random ized to double-blind treatment. Two patients failed to return after the baseline visit and therefore had no efficacy data. Accordingly, data from 245 patients were analyzed for efficacy. Balance was achieved in the number of patients randomized to the four treatment groups, and there were no significant differences among the treatment groups in demographic and pretreatment characteristics ( Table 2) .
All 247 patients met the entry criteria ofhaving a minimum MSC severity score . There were no statistica lly significant differences among the four treatment groups at baseline in the mean TSC and MSC severity scores.
Primary Eff icacy Parameters
Both the azelasti ne 2 sprays bid and 2 sprays qd dosage groups had mean percent improvements in the TSC and MSC severity scores that were clinically significant (~50% improvement over placebo) at each evaluation poi nt. After I week of treatment, the mean percent improvements in the Week 1
Week 2 Overall ex perience reports. The study protocol was approved by an Institutional Review Board.
Statistical Analysis
Previous investigations with azelastine demonstrated that 61 patients per treatment group would be ample to detect a difference of 45% between the active treatment groups and placebo for the TSC severity score with an alpha level of .05 and a power of 80%.
Overall eval uations were based on intent-to-treat approaches which included all patients with at least one postbaseline observation. An endpoint analysis was based on the last observed change noted for each patient using all available postbaseline data. The primary evaluations of treatment effect for mean percent change from baseline for the TSC and MSC severity sco res were performed by analyses of covariance, with terms for treatment, center, and baseline value (as a covariate) incorporated in the model. Key comparisons of each active treatment versus placebo were assessed by t-tests using the mean square error from the covariance analysis. Treatment differences for global evaluations (by both investigators and patients) and changes in nasal examination find ings were analyzed by the Cochran-Mantel-Haenszel test.
At each evaluation period (the end of weeks I and 2), the mean for all the morning individual rhinitis symptom scores and the mean for all the evening individual rhinitis symptom scores were calcu lated. The daily average for each weekly evaluation period was then calculated based on the mean of ® ...than any other chair in its class offers! That's the DMI T224. The Administer cautiously toallergic patients. Pseudomembranous colitis hasbeen reported with virtually allbroad-spectrum antibiotics. Itmust be considered in differential di agnosis of antibiotic-associated di arrhea. Colon flora is altered by broad-spectrum antibiotic treatment, possibiy resulting inantibiotic-associated colitis. (Figure 2 ) severity scores for the azelastine 2 sprays bid group (24% and 25%, respectively) were statistically significant (P< .00 I) compared to placebo (2% and 3%, respectively). Improvements in the TSC and MSC severity scores for the azelastine 2 sprays qd group after I week of treatment (9% and 8%, respectively), although clinically superior to placebo, were not statistically significant.
TSC (Figure I) and MSC
At week 2, the azelastine 2 sprays bid group retained clinically and statistically significant (PS;.02) mean percent improvements in both the TSC and MSC severity scores (28% for both scores) compared with placebo (10% and II %, respectively). The mean percent improvement for the azelastine 2 sprays qd group exceeded those for placebo for both the TSC and MSC severity scores, but the differences did not reach statistical significance.
On endpoint analyses, the mean percent improvements in the TSC and MSC severity scores for the azelastine 2 sprays bid group (28% and 29%, respectively) and the 2 sprays qd group (15% and 14%, respectively) continued to demonstrate clinical superiority over placebo (8% for both) and were statistically significant (PS;.005)versus placebo for the azelastine 2 sprays bid group.
Overall, combining both weeks of treatment, the mean percent improvements in the TSC (26%) and MSC (27%) were clinically and statistically significant (PS;.OO I) for the azelastine 2 sprays bid group versus placebo (4% to 6%). Treatment with the azelastine 2 sprays qd group resulted in clinically significant overall mean percent improvements in the TSC (12%) and MSC (II %), but the differences were not statistically significant compared to placebo.
Treatment with chlorpheniramine maleate 12 mg bid resulted in mean percent improvements in the TSC and MSC severity score s that were statistically significantly greater than placebo after each week of treatment, overall across both weeks, and for the endpoint analysis.
Secondary Efficacy Parameters
Results of the analyses for the secondary efficacy variables were generally consistent with the pattern of therapeutic response with azelastine for the mean percent improvements in the TSC and MSC severity scores. Treatment with both azelastine 2 sprays bid and 2 sprays qd resulted in clinically significant improvements in all individual symptoms of the TSC severity score which, for the bid group, were also statistically significant versus placebo (Figure 3 ). Importantly, each symptom 's percent improvements were generally comparable, with the magnitude of improvement being proportional to each symptom's contribution to the TSC severity score at baseline (Table 3) • safety and effectiveness have notbeen determined inpregnancy, lactation, and Inf ants less than 1 month old. Ceclor penetrates mottler's milk. Exercise caution inprescribing formass patients.
Adverse Reactions: (percentage ofpatients)
Therapy-related adverse reactions are uncommon. Those reported include: • Hypersensitivity reactions have been reported in about 1.5% of patients and Include morbilliform eruptions (1 In100). Pruritus, urticaria, and positive Coombs' tests each occur in less ttlan 1 in 200 pati ents. Casesofserum-sickness-like reactions have been reported with the useofCeclor. These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied byarthritislarltlralgia, with orwittlout fever, and differ from classic serum sickness in thatthere is infrequently associated lymphadenopathyand proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. While further Investigation is ongoing, serum-sickness-like reactions appear tobedue to hypersensitivity and more often occur during or following a second (orsubsequent) course of therapy withCeclor. Such reactions have beenreported more frequentiy Inchildren than Inaduits with anoverall occurrence ranging from 1in 200 (0.5%)inone focused trial to 2 In8,346 (0.024%) in overall clinical trials (with anincidence in children inclinical trials of0.055%) to 1 in38,000 (0.003%) inspontaneous event reports. Signs and symptoms usually occur a fewdays after initiation of ttlerapy and subside within a fewdays after cessation of therapy; occasionally thesereactions have resulted In hospitalization, usually of short duration (median hospit alization =2 to 3 days, based onpostmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mildto severe at the timeof admission with more of the severe reactions occurring in children. Antihistamines andglueD-corticolds appear toonhance resolution ofthesigns and symptoms. No serious sequelae have been reportod.
• Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rar ely. Anaphylaxis may bemore common inpatients withahistory ofpenicillin allergy. • Gastrointestinal(mostly diarrhea): 2.5%. • Symptoms ofpseudomembranous colllis may appear either during orafter antibiotic treatment.
• As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic Jaundice have been reported rarely. • Rarely, reversible hyperactivity, agitation, nervousness, Insomnia, confusion, hypertonia, dizziness, hallucinations,and somnolence have boen reported. • Other: eosinophilia, 2%: genital pruritus or vaginitis, less than 1%and, rarely, thrombocytopenia and reversible interstitial nephritis. Figure 4 ].
There were no differences between the azelastine nasal spray groups and the placebo group in the percentage of patients who had a change in the nasal examination parameters (turbinate mucosa and nasal secretion) . 
Discussion
Allergic rhinitis is a disease that manifest s as a complex of many symptoms; and, although a single allergic rhinitis 
Safety Parameters
There were no clinically meaningful within-group changesor betweengroup differences relative to vital signs or body weight. Pretreatment and posttreatment physical examination findings were unremarkable. In addition, there were no meaningful between -treatment differences in the pre-to end-of-treatment mean laboratory values .
Azelastine nasal spray was well tolerated. Three azelastine-treated patients (two from the 2 sprays qd group and one from the 2 sprays bid group) discontinued therapy because of an adverse experience (epistaxis in two, bitter taste in one). The most frequently report ed adverse experiences are shown in Table 4 . The incidences of adverse experiences in the azelastine groups did not differ statistically from the incidences in the placebo group with the exception of taste perversion. The majority of patients who reported a taste-related problem noted that it was a bitter taste of brief duration that occurred immediately after use of the nasal solution. In these patients, the bitter taste was likely due to the inherent bitter taste of the drug itself. Only one patient in the 2 sprays qd group and 4 patients in the 2 sprays bid group experienced actual dysgeusia, an altered perception of taste . clinically apparent within 2 hou rs, a durat ion of effect for 12 to 24 hours,and isactive incontrolling all symptomsof SAR.23,24 Importantly,aze last ine nasal solution demonstrated clinica l activity on nasal co nges tion and on non-nasal as we ll as well as nasal symptoms . Tr eatment with aze lastine 2 spra ys qd and 2 sprays bid resulted in cl inica lly significant imp rovem ents in all of the indiv idual rhinitis symptoms of the TSC severity score, not j ust one of a few symptoms, and the magnitude of the effect on eac h symptom was proportional to that symptom's con tribution to the TSC severi ty sco re at baselin e. symp tom may predomi nate in any one individual, it is traditional and clinically rational to look at a drug 's impac t on all the rhinitis symptoms (TSC) as the best indicator of a drug's therapeutic effect. In this clinical trial, the primary efficacy parameters were the MSC severity score, co nsisting of five symptoms which predomi nate in the rhin itis symptom profile (sneezes, runn y nose/ sni ffles, nose blows, itchy nose, watery eyes) and the TSC severity score, co nsis ting of the MSC , plu s three addit ional sym p, toms (itchy eye s/throat/palate, cough, postnasal dr ip). Result s of th is trial demonstrate that azelastine nasal so lution is effective in the treat ment of patien ts with symptomatic SAR. For the aze lastine 2 sprays bid group, these improvements were cli nically and statis tica lly significantly superior to placeb o at all eva luat ion poin ts. For the 2 sprays qd gro up, these improvement s were cl inica lly, but not statistically sign ifica nt.
Previous SAR studies in which patients eva luated their symptoms at hourly intervals using these same MSC and TSC severity scores as primary indicators of efficacy have shown that azelastine nasal solution (2 spray s/nostril qd and 2 sprays/nostril bid) has a rapid onset of action that is Two do sage regimens of azelastine nasal solution were evaluated over a 2-week period in the treatment of seasonal allergic rhinitis. Primary efficacy parameters were the Total and Major Symptom Complex seve rity scores. Azelastine nasal solution qd and bid resulted in improvement s in the Total and Major Symptom Complex severity scores at all evaluation point s; for the azelastine bid group, the se improvement s were statistically significant compared to placebo. Th ere were no notable adv erse effects on safety parameters. Thi s stud y utilized a doubl edummy de sign technique, therefore saline nasal spray was used in conjunction with chlorpheniramine maleate tablets and also as placebo for blinding purposes. Because the topical instillation of saline by itself has been demonstrated to improve rhinitis sy mptoms.F it may have contributed to some of the effectiveness noted in tho se patients who received placebo.
Adverse experiences were few in number, and there were no notable adverse effects on laboratory values, vital signs , or phy sical examination findings including nasal examination s. Th e mo st frequently reported adverse experience con sidered related to azela stine was taste perversion. In the majority of ca ses, it was of immedi ate onset, of short duration, and seemed to be related to the inherent bitter taste of the medication and not to a systemic effect.
Unlike topical decongestants, azelastine has not demonstrated a rebound effect upon discontinuation. Furthermore, it doe s not require precautions associated with topical corti co steroids regarding locali zed infections of the nose and pharynx, nasal septa l perforations, and increased intraoccular pre ssure.
Thi s study showed that azela stine nasal solution admini stered either once or twice daily is clinically effective in treating the symptoms of SAR . The favorable safety profile of azelastine nasal spray together with its rapid onset and prolonged duration of action in relieving rhinitis symptoms make it a useful addition to therapies available for SAR with possible advantages over available topical treatments. 
